BridgeBio Oncology Therapeutics, Inc. Finance Lease, Right-of-Use Asset, Amortization
BridgeBio Oncology Therapeutics, Inc. (BBOT) reported Finance Lease, Right-of-Use Asset, Amortization of $330.00 thousand for the 12-month period ending 2025-12-31, per its POS AM filed 2026-04-30.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseRightOfUseAssetAmortization · last filed 2026-04-30
- BridgeBio Oncology Therapeutics, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2025-12-31 was $110.00K.
- BridgeBio Oncology Therapeutics, Inc. finance lease, right-of-use asset, amortization for the quarter ending 2024-12-31 was $0.00.
| Period end | Finance Lease, Right-of-Use Asset, Amortization 3 month | Finance Lease, Right-of-Use Asset, Amortization 9 month | Finance Lease, Right-of-Use Asset, Amortization 12 month |
|---|---|---|---|
| 2025-12-31 | $110.00K derived: POS AM 12 month − 10-Q 9 month · filed 2026-04-30 | $330.00K POS AM · filed 2026-04-30 | |
| 2025-09-30 | $220.00K 10-Q · filed 2025-11-12 | ||
| 2024-12-31 | $0.00 derived: POS AM 12 month − 10-Q 9 month · filed 2026-04-30 | $0.00 POS AM · filed 2026-04-30 | |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |